// App-Quantinova.ai

388 : Pathway-directed high throughput drug screen identifies PI3K inhibitors that synergistically potentiate anti-tumor activity of HDAC inhibitors in mycosis fungoides and Sezary syndrome

Researchers

Presenter

  • Chen-Yen Yang

Principal Investigators

  • Razan Faraj

  • Taha Rakhshandaroo

  • Shervin Afghani

  • Laura Pincus

  • Sourav Bandyopadhyay

  • Frank McCormick

  • Weiyun Ai

Medical Centers

  • UCSF, San Francisco, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Mycosis fungoides

  • T-cell lymphoma

  • Sezary syndrome

  • Lymphomas

  • Solid malignancies

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved